159 related articles for article (PubMed ID: 10697397)
1. [Stem cell factor (SCF) in diagnosis and monitoring of non-small-cell lung cancer].
Mroczko B; Szmitkowski M; Czygier M
Pol Arch Med Wewn; 1999 Mar; 101(3):213-8. PubMed ID: 10697397
[TBL] [Abstract][Full Text] [Related]
2. [Granulocyte macrophage-colony stimulating factor (GM-CSF) in diagnosis and monitoring of non-small cell lung cancer].
Mroczko B; Szmitkowski M; Furman M; Czygier M
Pol Arch Med Wewn; 1998 Mar; 99(3):195-202. PubMed ID: 9760805
[TBL] [Abstract][Full Text] [Related]
3. [Granulocyte colony stimulating factor (G-CSF) in diagnosis and monitoring of non-small-cell lung cancer (NSCLC)].
Mroczko B; Szmitkowski M; Czygier M
Pol Arch Med Wewn; 2000; 103(3-4):163-8. PubMed ID: 11236243
[TBL] [Abstract][Full Text] [Related]
4. [Macrophage-colony stimulating factor (M-csf) in diagnostic and monitoring of non-small-cell lung cancer (NSCLC)].
Mroczko B; Szmitkowski M
Pol Arch Med Wewn; 2001 Mar; 105(3):203-9. PubMed ID: 11680264
[TBL] [Abstract][Full Text] [Related]
5. Stem cell factor and granulocyte-macrophage-colony stimulating factor as candidates for tumour markers for non-small-cell lung cancer.
Mroczko B; Szmitkowski M; Niklinski J
Clin Chem Lab Med; 1999 Oct; 37(10):959-62. PubMed ID: 10616749
[TBL] [Abstract][Full Text] [Related]
6. [Interleukin 3 (IL-3) in diagnosis and monitoring of non-small-cell lung cancer].
Mroczko B; Szmitkowski M; Czygier M
Przegl Lek; 1999; 56(12):763-6. PubMed ID: 10789186
[TBL] [Abstract][Full Text] [Related]
7. Granulocyte-Colony stimulating factor and macrophage-colony stimulating factor in patients with non-small-cell lung cancer.
Mroczko B; Szmitkowski M; Niklinski J
Clin Chem Lab Med; 2001 May; 39(5):374-9. PubMed ID: 11434384
[TBL] [Abstract][Full Text] [Related]
8. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer.
Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS
Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383
[TBL] [Abstract][Full Text] [Related]
9. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
[TBL] [Abstract][Full Text] [Related]
10. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
[TBL] [Abstract][Full Text] [Related]
11. Utility of serum cytokeratin 19 fragment (CYFRA 21-1) and carcinoembryonic antigen (CEA) as tumour markers for non-small cell lung cancer.
Chantapet P; Riantawan P; Lebnak P; Getngern P
J Med Assoc Thai; 2000 Apr; 83(4):383-91. PubMed ID: 10808698
[TBL] [Abstract][Full Text] [Related]
12. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.
Tas F; Aydiner A; Topuz E; Yasasever V; Karadeniz A; Saip P
J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326
[TBL] [Abstract][Full Text] [Related]
13. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and carcinoembryonic antigen (CEA) as tumour markers in bronchogenic carcinoma.
Huang MS; Jong SB; Tsai MS; Lin MS; Chong IW; Lin HC; Hwang JJ
Respir Med; 1997 Mar; 91(3):135-42. PubMed ID: 9135852
[TBL] [Abstract][Full Text] [Related]
14. Serological proteome analysis approach-based identification of ENO1 as a tumor-associated antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer.
Dai L; Qu Y; Li J; Wang X; Wang K; Wang P; Jiang BH; Zhang J
Oncotarget; 2017 May; 8(22):36664-36673. PubMed ID: 28456790
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer.
Nisman B; Amir G; Lafair J; Heching N; Lyass O; Peretz T; Barak V
Anticancer Res; 1999; 19(4C):3549-52. PubMed ID: 10629651
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of serum C-reactive protein (CRP) and cytokeratin 19 fragments (Cyfra 21-1) but not carcinoembryonic antigen (CEA) in surgically treated patients with non-small cell lung cancer.
Szturmowicz M; Rudziński P; Kacprzak A; Langfort R; Bestry I; Broniarek-Samson B; Orłowski T
Pneumonol Alergol Pol; 2014; 82(5):422-9. PubMed ID: 25133810
[TBL] [Abstract][Full Text] [Related]
17. [Diagnostic usefulness of selected tumor markers (CA125, CEA, CYFRA 21-1) in bronchoalveolar lavage fluid in patients with non-small cell lung cancer].
Dabrowska M; Grubek-Jaworska H; Domagała-Kulawik J; Bartoszewicz Z; Kondracka A; Krenke R; Nejman P; Chazan R
Pol Arch Med Wewn; 2004 Jun; 111(6):659-65. PubMed ID: 15508787
[TBL] [Abstract][Full Text] [Related]
18. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
[TBL] [Abstract][Full Text] [Related]
19. CYFRA 21-1 as a Predictive Marker for Non-small Cell Lung Cancer Treated with Pemetrexed-based Chemotherapy.
Sone K; Oguri T; Nakao M; Kagawa Y; Kurowaka R; Furuta H; Fukuda S; Uemura T; Takakuwa O; Kanemitsu Y; Ohkubo H; Takemura M; Maeno K; Ito Y; Sato H; Muramatsu H; Niimi A
Anticancer Res; 2017 Feb; 37(2):935-939. PubMed ID: 28179355
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Cyfra 21-1 as a marker for lung cancer.
Najemnik C; Mohn-Staudner A; Vetter H; Kokron O; Baumgartner G; Scheiner W; Zwick H; Koderhold G; Alth G; Dudczak R
Wien Klin Wochenschr; 1996; 108(15):467-72. PubMed ID: 8806188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
